

PROGRESS REPORT ON ACCESS TO HEPATITIS C TREATMENT

**FOCUS ON OVERCOMING BARRIERS
IN LOW- AND MIDDLE-INCOME COUNTRIES**

MARCH 2018



A patient holds her hepatitis C medicines
at the MSF hepatitis C clinic at Preah
Kossamak Hospital in Phnom Penh, Cambodia
CREDIT: TODD BROWN



PROGRESS REPORT ON ACCESS TO HEPATITIS C TREATMENT

**FOCUS ON OVERCOMING BARRIERS
IN LOW- AND MIDDLE-INCOME COUNTRIES**

MARCH 2018

WHO/CDS/HIV/18.4

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries, March 2018. Geneva, Switzerland: World Health Organization; 2018 (WHO/CDS/HIV/18.4). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout by: blossoming.it

Printed in Switzerland

CONTENTS

Acknowledgements	iv
Abbreviations and acronyms	v
Executive summary	vii
1 Introduction	2
2 Status of the hepatitis C treatment response	4
3 Expanding access to hepatitis C treatment: challenges and opportunities	9
4 Overcoming access barriers: experiences of selected countries	18
5 Conclusion	30
Appendix. Drug profiles	43
References	46
Annexes	50
Annex 1. Prices of HCV diagnostics	50
Annex 2. Countries and territories not included in voluntary license agreements	51

ACKNOWLEDGEMENTS

This publication was developed jointly by the Department of HIV and Global Hepatitis Programme (GHP) and the Department of Essential Medicines and Health Products (EMP) of the World Health Organization (WHO) in a process led by Françoise Renaud, Peter Beyer and Marc Bulterys. The contributions of Fernando Pascual Martinez, who managed the data collection and conducted the interviews, and Hein Marais, who was the lead writer, are gratefully acknowledged.

We particularly thank colleagues in ministries of health and in WHO regional and country offices for their contributions, as well as Yvan Hutin (who contributed the 2016 update of global treatment and testing coverage data), Bernadette Cappello, Andrew Rintoul, Matthias Stahl, Robyn Meurant, Irena Prat, Anita Sands, Nicole Homb, Nick Walsh and Daniel Low-Beer. Bandana Malhotra edited the report and Oyuntungalag Namjilsuren provided communication coordination support.

Andrew Ball, Sarah Garner, Suzanne Hill and Gottfried Hirnschall provided overall leadership and coordination.

The following persons were interviewed for the report: Morgane Ahmar (Coalition Plus, Morocco), Adele Benzaken (Departamento de DST, Aids e Hepatites Virais, Brazil), Pascale Boulet (Drugs for Neglected Diseases *initiative*, Switzerland), Jessica Burry (Médecins Sans Frontières, Switzerland), Esteban Burrone (Medicines

Patent Pool, Switzerland), María Butti (Hospital Vall d'Hebrón, Spain), Jean Michel Caudron (United Nations Development Programme, Switzerland), Graciela Diap (Drugs for Neglected Diseases *initiative*, Switzerland), Nicolas Durier (Dreamlopmements, Thailand), Gamal Esmat (Cairo University, Egypt), Charles Gore (World Hepatitis Alliance, UK), Céline Grillon (Médecins du Monde, France), Andrew Hill (Department of Translational Medicine, University of Liverpool, United Kingdom), Giten Khwairakpam (Treat Asia, Thailand), Sharon Lewin (Peter Doherty Institute for Infection and Immunity, Australia), Ludmila Maisat (Medicines Patent Pool, Switzerland, previously with the Alliance for Public Health, Ukraine), Othman Mellouk (International Treatment Preparedness Coalition, Morocco), Leena Menghaney (Médecins Sans Frontières, India), Chase Perfect (Coalition Plus, France), Ventzislava Petrov-Sánchez (Agence nationale de recherches sur le sida et les hépatites virales, France), Sangeeta Shashikant (Third World Network, India), Marcelo Silva (Hospital Austral, Argentina), Ellen 't Hoen (Medicines Law & Policy, The Netherlands), Karin Timmermans (UNITAID, Switzerland), David Thomas (Johns Hopkins School of Medicine, USA).

Financial acknowledgments

Funding support for the development of the report was kindly provided by UNITAID. WHO also thanks other institutions that provided staff time and contributed to the production of the report.

ABBREVIATIONS

API	active pharmaceutical ingredient
BMS	Bristol-Myers Squibb
CHAI	Clinton Health Access Initiative
DAA	direct-acting antiviral (medicine)
DCV	daclatasvir
DNDi	Drugs for Neglected Diseases <i>initiative</i>
D+o/p/r	dasabuvir + ombitasvir/paritaprevir/ritonavir
EMA	European Medicines Agency
Global Fund	Global Fund to Fight AIDS, Tuberculosis and Malaria
HCV	hepatitis C virus
HIC	high-income country
HIV	human immunodeficiency virus
LDV	ledipasvir
LIC	low-income country
LMIC	lower-middle-income country
MoH	Ministry of Health
NGO	nongovernmental organization
OECD	Organisation for Economic Co-operation and Development
RDV	ravidasvir
RNA	ribonucleic acid
SMV	simeprevir
SOF	sofosbuvir
TRIPS	Agreement on Trade-Related Aspects of Intellectual Property Rights
UN	United Nations
UMIC	upper-middle-income country
USA	United States of America
US FDA	United States Food and Drug Administration
VEL	velpatasvir



WHO promotes and supports

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25985

